title: Thyroid Stimulating Hormone Suppression in the Long-term Follow-up of Differentiated Thyroid Cancer.
abstract: Differentiated thyroid cancer is the most common form of thyroid cancer and its prognosis is favourable in most cases. Suppression of thyroid stimulating hormone (TSH) by supra-physiological thyroid hormone replacement has been the mainstay of long-term management for over 60 years. However, evidence for a beneficial outcome of TSH suppression is conflicting and intervention must be balanced against adverse effects, particularly affecting the cardiovascular system and skeleton. Here we discuss the role of TSH suppression in the long-term management of differentiated thyroid cancer in the context of risk stratification for disease recurrence and the latest clinical guidelines.
authors.affiliation: Molecular Endocrinology Laboratory, Imperial College London, London, UK.
authors.forename: B
authors.initials: B
authors.lastname: Freudenthal
authors.affiliation: Molecular Endocrinology Laboratory, Imperial College London, London, UK. Electronic address: graham.williams@imperial.ac.uk.
authors.forename: G R
authors.initials: GR
authors.lastname: Williams
mesh_terms: D020249:Hormone Replacement Therapy / Q000009:adverse effects / Q000379:methods; D006801:Humans; D011379:Prognosis; D012306:Risk; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000601:surgery; D013965:Thyroidectomy / Q000379:methods*; D013972:Thyrotropin / Q000097:blood / Q000187:drug effects*; D013974:Thyroxine / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D013972:Thyrotropin; D013974:Thyroxine
keywords: Differentiated thyroid cancer; TSH suppression; subclinical thyrotoxicosis